David Crow
Cancer Pill Costs Soar as Drug Companies Retain Pricing Power
Doctors have to act as financial planners to find treatment that patients can afford
Financial Times, 2017
What's inside?
In the United States, doctors must choose between the best cancer treatments and the ones their patients can afford.
Recommendation
Financial Times senior US business correspondent David Crow describes the cruel reality of the 25% of American cancer patients who find themselves forced to choose between the best treatments and the ones they can afford. The drug companies don’t accept responsibility, instead blaming insurance companies and pharmacy benefit managers for not passing rebates on to patients. However, rebates don’t apply to cancer medications, and the price hikes are now so widely criticized that US president Donald Trump is threatening to intervene. getAbstract recommends this analysis to anyone who believes in affordable health care for all.
Summary
About the Author
David Crow is a senior US business correspondent for the Financial Times, covering telecoms, technology and pharmaceuticals.
Comment on this summary